BMS’ Breyanzi (lisocabtagene maraleucel) Receives the US FDA’s Approval for Adults With R/R Large-B-Cell Lymphoma

 BMS’ Breyanzi (lisocabtagene maraleucel) Receives the US FDA’s Approval for Adults With R/R Large-B-Cell Lymphoma

BMS’ Deucravacitinib Demonstrate Superiority Over Otezla (apremilast) in P-III POETYK PSO-2 Study for Plaque Psoriasis

Shots:

  • The approval is based on pivotal TRANSCEND NHL 001 (017001) study assessing Breyanzi in 268 patients with 3L+R/R LBCL including patients with a broad range of histologies and high-risk disease. Breyanzi was administered in the inpatient & outpatient settings
  • Results: ORR (73%); CR (54%); PR (19%); mDOR (16.7mos.) in all responders; patients with best response or PR, mDOR (1.4mos.); patients achieving CR, 65% had remission lasting at least 6mos. and 62% had remission lasting at least 9mos.
  • Breyanzi is a CD19-directed CAR T cell therapy with defined composition and 4-1BB costimulatory domain. Additionally, the US FDA has granted ODD, RMAT and BT Designation to the therapy

Click here, Click here ­to­ read full press release/ article | Ref: PRNewswire, BMS | Image: PRNewswire, BMS

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post